Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Mid Cap Fund median (34 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 28 Nov 2022 – 20 Aug 2026, limited by HSBC Midcap Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | HSBC Midcap Fund | Nifty Midcap 150 |
|---|---|---|
| 28 Nov 2022 | ₹100.00 | ₹100.00 |
| 21 Mar 2023 | ₹95.53 | ₹94.03 |
| 13 Jul 2023 | ₹110.34 | ₹112.44 |
| 03 Nov 2023 | ₹123.30 | ₹123.23 |
| 25 Feb 2024 | ₹151.22 | ₹150.92 |
| 17 Jun 2024 | ₹177.68 | ₹172.11 |
| 09 Oct 2024 | ₹196.53 | ₹182.26 |
| 30 Jan 2025 | ₹167.42 | ₹162.27 |
| 23 May 2025 | ₹179.25 | ₹173.58 |
| 14 Sep 2025 | ₹193.96 | ₹179.34 |
| 05 Jan 2026 | ₹198.07 | ₹187.56 |
| 29 Apr 2026 | ₹210.29 | ₹184.70 |
| 20 Aug 2026 | ₹233.87 | ₹194.49 |
| Metric | HSBC · Direct NAV ₹542.11 Very High risk ★★★★☆ | Category median Mid Cap Fund · 34 funds |
|---|---|---|
| +21.43% | +9.87% | |
| +26.45% | +19.74% | |
| — | +17.84% | |
| — | +17.01% | |
| +25.61% | +19.29% | |
| +24.09% | — | |
| +26.34% | +20.53% | |
| — | +19.07% | |
| — | +18.49% | |
| Risk | ||
| 18.55% | 16.20% | |
| 1.07 | 0.83 | |
| 1.45 | 1.14 | |
| -25.96% | -32.95% | |
| Nifty Midcap 150 | — | |
| +7.31% | +2.33% | |
| 1.03 | 0.94 | |
| 116.4% | 98.4% | |
| 88.2% | 87.8% | |
| 1.20% | 0.97% | |
| ₹13,701Cr | ₹7,594Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 7% | 40% | |
| Mayank Chaturvedi | — | |
| 28 Nov 2022 | — | |
| 81 | — | |
| 37.0% | — | |
| 1.1% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.